---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-080308"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2026-07-02T20:05:21+00:00"
generated_at: "2026-07-02T20:07:25.518855+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Barinthus Biotherapeutics gets Nasdaq extension to Dec 28, 2026; listing moved to Capital Market

## Summary
- Received 180-day extension from Nasdaq until Dec 28, 2026 to regain $1.00 minimum bid price for ADSs.
- ADS listing transferred from Nasdaq Global Market to Nasdaq Capital Market effective July 2, 2026.
- Company may consider reverse stock split to regain compliance; no assurance of success.
- If bid price does not close at $1.00 for 10 consecutive days by Dec 28, 2026, ADSs may be delisted.

## SEC filing metadata
- accession: 0001104659-26-080308
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2026-07-02T20:05:21+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465926080308/0001104659-26-080308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465926080308/tm2619582d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-080308
- JSON: https://secwatch.observer/filing/0001104659-26-080308.json
- Plain text: https://secwatch.observer/filing/0001104659-26-080308.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.